What does IGF-1 LR3 change?

It reduces affinity for the IGF binding proteins, raising the free fraction available to engage receptors at a given total concentration.

Does that mean it causes cancer?

No such finding exists and no clinical programme has examined it. What can be said is that it bypasses a regulatory system whose biology is well documented.

Why was it never developed clinically?

Bypassing IGFBP regulation is useful in a culture dish where it is a nuisance. In an organism the same system regulates a growth factor acting on every tissue.

IGF-1 LR3

A Regulatory System, Deliberately Evaded

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

IGF-1 LR3's defining feature is reduced affinity for the binding proteins that normally sequester circulating IGF-1. Those proteins are a regulatory system, not an obstacle, and the compound exists to bypass them — which sits in tension with what the Laron literature reports.

Key facts

What LR3 removes: IGF binding protein affinity
What that system does: Restrains free IGF-1 availability
Laron finding: Congenital deficiency, cancer not observed
IGF-1R oncology: Pursued precisely on that rationale
LR3 clinical development: None — a cell culture reagent
WADA: Prohibited at all times, class S2

What the binding protein system is for

Six binding proteins hold the overwhelming majority of circulating IGF-1, largely in a ternary complex with IGFBP-3 and the acid-labile subunit. Bound IGF-1 cannot engage its receptor. The system functions simultaneously as a reservoir and a brake, keeping a large circulating pool while holding the active free fraction small and regulated.

Why a growth factor needs a brake

IGF-1 receptors are present on essentially every tissue, and the signal promotes proliferation and opposes cell death. A signal with that reach and that effect requires tight control, and the binding protein system is that control. It is not an inefficiency in the design that an engineer could improve upon.

Research material referenced

IGF-1 LR3 1mg — third-party HPLC tested

View — £37.99

What LR3 does to it

Arginine at position 3 and a thirteen-residue N-terminal extension both reduce binding protein affinity. The result is a substantially larger free fraction at the same total concentration. That is the entire purpose of the molecule, and in its intended setting — a culture dish, where secreted binding proteins are an experimental nuisance — it is a sensible design.

The tension worth stating

The Laron literature reports that congenital IGF-1 deficiency is associated with absence of cancer, and IGF-1R was pursued as an oncology target on exactly that reasoning. A compound engineered to maximise free IGF-1 availability sits in obvious tension with those findings. Setting them beside each other is the honest thing to do, and this site sells the compound.

What this does and does not establish

It does not establish that IGF-1 LR3 causes cancer. No such finding exists, no clinical programme has examined it, and asserting it would be a claim without evidence. What it establishes is that the compound bypasses a regulatory system whose biology is well documented, and that the documentation points in a direction worth knowing about.

Why the compound stayed in a dish

This is a reasonable part of the explanation for why LR3 was never taken into clinical development. Bypassing IGFBP regulation is desirable in vitro, where it is a nuisance variable, and is a different proposition in an organism where the same system regulates a growth factor acting on every tissue. It remains investigational nowhere, unlicensed everywhere, and prohibited in sport under WADA class S2 at all times.

Extended research context

The IGF-1 LR3 deep dive

Deep dive: the design that runs backwards from everything else here

Almost every engineered compound in this catalogue solves the same problem in the same direction. Semaglutide attaches a C18 diacid, retatrutide and tirzepatide a C20, all to bind serum albumin and extend duration. CJC-1295's DAC goes further and binds albumin covalently at Cys34. The strategy throughout is to add binding, so the molecule survives longer in circulation. IGF-1 LR3 does the reverse. Its two modifications - arginine replacing glutamate at position 3, and a thirteen-residue N-terminal extension - exist to REMOVE binding, specifically to the IGF binding proteins that sequester the overwhelming majority of circulating IGF-1 in a ternary complex with IGFBP-3 and the acid-labile subunit. Same bound-free equilibrium, engineered in the opposite direction. The reason is that the two families face opposite constraints: an incretin peptide is cleared too fast to be useful, while IGF-1 is held too tightly to be available. Baxter's 1994 review in Hormone Research is the standard account of just how tightly.

Deep dive: a certificate written for the wrong failure mode

This is a recombinant protein, and it fails differently from everything else on this site. A synthetic peptide accumulates deletion sequences, because each coupling is slightly less than complete - at 99% efficiency a 39-mer finishes around 68% full-length, and those impurities differ by one residue's mass and show up in a mass spectrum. Ribosomal synthesis does not fail that way at all; a host cell builds the protein correctly or not at all. What contaminates the product instead is everything else the cell contained: host cell proteins, host DNA, and in bacterial systems endotoxin, which is not a protein, does not appear in a protein purity figure, and needs its own assay entirely. Layered on top is a failure mode with no peptide equivalent. This protein has three disulfide bonds, meaning six cysteines that can pair fifteen ways of which one is correct - and Milner and colleagues showed in the Biochemical Journal in 1995 that B-domain mutations influence oxidative folding, which is directly relevant since position 3 sits in the B-domain. A misfolded isomer has identical mass, identical composition, and is invisible to mass spectrometry. A certificate reading exactly like a synthetic peptide's is testing for problems this production route does not have while missing the ones it does.

Deep dive: an approved relative, and why that raises the risk rather than lowering it

Unusually for this catalogue, a licensed IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency - Petriczko and colleagues reported on it in 2019 and Denaite and colleagues in Frontiers in Pediatrics in 2024. That is a real approval with real clinical evidence. It covers the native seventy-residue hormone. LR3 is an eighty-three-residue engineered analogue whose defining feature is deliberately altered binding behaviour, holds no marketing authorisation anywhere, and has essentially no primary literature under its own name - searches for IGF-1 LR3 and Long R3 IGF-1 return nothing. A nearby approval invites the inference that the analogue is somehow covered by it, and that inference is the most consequential error available in this category. Separately and unconditionally: IGF-1 and its analogues sit in WADA class S2, prohibited at all times, with the list extending to related substances and mimetics precisely so that structural modification creates no exemption.

Research applications

▸Cell culture supplementation where secreted IGFBPs confound dosing
▸IGF binding protein interaction and affinity studies
▸Recombinant protein expression and purification methodology
▸Disulfide folding and oxidative refolding research
▸Comparative work on engineered versus native growth factors
▸Anti-doping analytical method development

Handling checklist

✓Expect no PubChem record - proteins are indexed in UniProt (native IGF-1 is P05019)
✓Read the certificate for host cell protein, host DNA and endotoxin, not deletion sequences
✓Understand that mass spectrometry cannot detect a misfolded disulfide isomer
✓Treat loss of fold as the principal failure mode - it leaves mass unchanged
✓Avoid shaking and foaming; interfaces unfold proteins and aggregation is irreversible
✓Use low-binding consumables; adsorption is significant at microgram quantities
✓Aliquot before freezing - freeze-thaw is worse for a folded protein than a short peptide

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading mecasermin's approval as covering IGF-1 LR3

Fix: Increlex is native 70-residue rhIGF-1. LR3 is an 83-residue engineered analogue with altered binding, unlicensed everywhere. The approval does not transfer.

✗ Expecting a synthetic-peptide certificate for a recombinant protein

Fix: There are no deletion sequences here. The relevant tests are host cell protein, host DNA, endotoxin and something addressing conformation.

✗ Treating a clean mass spectrum as proof the protein is intact

Fix: A misfolded disulfide isomer has identical mass and composition. Only an activity or conformational assay addresses folding.

✗ Assuming absence from PubChem is a red flag

Fix: It is expected for a protein of this size - PubChem indexes small molecules, UniProt indexes proteins. This is unlike retatrutide, where absence is genuinely odd.

✗ Reading the cell-culture rationale as transferable

Fix: Bypassing IGFBP regulation is useful in a dish, where it is an experimental nuisance. In an organism the same system regulates a growth factor acting on nearly every tissue.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What does IGF-1 LR3 change?: It reduces affinity for the IGF binding proteins, raising the free fraction available to engage receptors at a given total concentration.
Does that mean it causes cancer?: No such finding exists and no clinical programme has examined it. What can be said is that it bypasses a regulatory system whose biology is well documented.
Why was it never developed clinically?: Bypassing IGFBP regulation is useful in a culture dish where it is a nuisance. In an organism the same system regulates a growth factor acting on every tissue.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum